FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 818 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer January 12, 2022 Introducing our new podcast for researchers February 4, 2022 EMA Recommends Extending Indications for Durvalumab July 17, 2025 Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma September 8, 2023 Load more HOT NEWS What Cancer Caregivers Should Know About Hospice Care at Home: A... The power of partnership – the unique alliance taking on brain... Shorter, More Intensive Radiation Safe after Surgery for Prostate Cancer How I Navigated the Challenges of 2 Colorectal Cancer Diagnoses As...
